MENU
+Compare
NVAX
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$8.18
Change
-$0.49 (-5.65%)
Capitalization
1.33B

NVAX Novavax Forecast, Technical & Fundamental Analysis

Novavax Inc is a biotechnology company that develops vaccines... Show more

Industry: #Biotechnology
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NVAX with price predictions
Jan 13, 2026

Momentum Indicator for NVAX turns positive, indicating new upward trend

NVAX saw its Momentum Indicator move above the 0 level on December 22, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

NVAX moved above its 50-day moving average on January 05, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NVAX crossed bullishly above the 50-day moving average on January 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for NVAX moved below the 200-day moving average on December 23, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVAX broke above its upper Bollinger Band on January 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.223) is normal, around the industry mean (30.106). P/E Ratio (4.075) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (1.279) is also within normal values, averaging (322.270).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NVAX is expected to report earnings to fall 60.94% to -48 cents per share on March 04

Novavax NVAX Stock Earnings Reports
Q4'25
Est.
$-0.49
Q3'25
Missed
by $0.71
Q2'25
Beat
by $0.68
Q1'25
Beat
by $3.36
Q4'24
Beat
by $0.09
The last earnings report on November 06 showed earnings per share of -125 cents, missing the estimate of -54 cents. With 7.55M shares outstanding, the current market capitalization sits at 1.33B.
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
700 Quince Orchard Road
Phone
+1 240 268-2000
Employees
1534
Web
https://www.novavax.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HEIIX12.62-0.04
-0.32%
Hennessy Equity and Income Institutional
EADIX20.37-0.07
-0.34%
Eaton Vance Global Equity Income A
RDWEX14.55-0.06
-0.41%
American Funds Dvlpg Wld Gr&Inc R4
STCZX18.61-0.08
-0.43%
Virtus Silvant Large-Cap Growth Stk R6
HSWTX22.25-0.17
-0.76%
Hartford Schroders International Stk R5

NVAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+11.87%
MRNA - NVAX
57%
Loosely correlated
+17.02%
BNTX - NVAX
44%
Loosely correlated
+4.90%
FHTX - NVAX
41%
Loosely correlated
+4.70%
XNCR - NVAX
39%
Loosely correlated
-1.62%
CCCC - NVAX
39%
Loosely correlated
+8.45%
More